ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with N.c.a. ¹⁷⁷Lu-Edotreotide (ITM-11) Vs. Everolimus at ASCO 2026

Why It Matters

The data prove that a targeted radiopharmaceutical can deliver both survival and quality‑of‑life benefits, positioning ¹⁷⁷Lu‑edotreotide as a potential new standard for GEP‑NET therapy.

Key Takeaways

• 177Lu‑edotreotide maintained QoL (+0.9) vs decline (-9.9).
• Time to QoL deterioration: 10.3 months vs 2.3 months.
• 43.5% improved QoL vs 30.4% on everolimus.
• Median improvement duration: 22 months vs 10.2 months.
• COMPETE met primary PFS endpoint, supporting regulatory filing.

Pulse Analysis

Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) represent a niche but growing segment of oncology, with limited systemic options beyond somatostatin analogues and the mTOR inhibitor everolimus. Everolimus, while extending progression‑free survival, often compromises patients’ daily functioning due to its side‑effect profile. Radiopharmaceuticals such as ¹⁷⁷Lu‑edotreotide aim to deliver high‑energy radiation directly to tumor cells, sparing surrounding tissue and potentially offering a more tolerable therapeutic window. ITM’s proprietary non‑carrier‑added formulation enhances tumor uptake, a technical advantage that has attracted investor interest and positioned the company at the forefront of precision oncology.

The COMPETE trial’s quality‑of‑life (QoL) results add a critical patient‑centric dimension to earlier efficacy findings. A modest QoL score increase (+0.9) versus a near‑10‑point decline for everolimus underscores a tangible benefit in daily functioning, while the 10.3‑month median time to deterioration suggests a prolonged period of stable health. Moreover, nearly half of the radiopharmaceutical arm reported meaningful improvement, with benefits lasting almost twice as long as the comparator. These outcomes resonate with clinicians who must balance tumor control against treatment‑related toxicity, and they may shift prescribing patterns toward therapies that demonstrably preserve quality of life.

From a regulatory and market perspective, the dual demonstration of progression‑free survival advantage and superior QoL strengthens ITM’s dossier for FDA review. A successful filing could unlock a multi‑billion‑dollar market, given the estimated 12,000 new GEP‑NET cases annually in the United States alone. The data also set a precedent for future radiopharma trials, encouraging sponsors to embed patient‑reported outcomes as primary or co‑primary endpoints. As payers increasingly demand value‑based evidence, ITM’s comprehensive trial design positions it to negotiate favorable reimbursement terms and to expand its pipeline into higher‑grade NETs through the ongoing COMPOSE study.